VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Vertex’s fifth CFTR modulator therapy, Alyftrek (vanza triple), is a next-in-class triple combination regimen that was approved by the FDA in December 2024 for treating people with CF aged six ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater ...

ALYFTREK or TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ALYFTREK should only be considered when there is a clear medical need and benefit ...

ALYFTREK There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions.